665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
Heymach, J., Kotecki, N., Prenen, H., Alonso, G., Lindsay, C.R., Barve, M., Thamer, C., Eigenbrod-Giese, S., Marotti, M.A., Van Lancker, G.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article